<table>
<thead>
<tr>
<th>TYPE</th>
<th>NAME</th>
<th>STATUS (in-participation)</th>
<th>Efficacy</th>
<th>SPECIFICS</th>
<th>ADDITIONAL DOSE/BOOSTER FOR mRNA VACCINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>MESSENGER RNA</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>(Comirnaty)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phase 2, 3 &amp; 4 (44,000)</td>
<td>67%</td>
<td>94%</td>
<td>Adult: 1 dose 5 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELA approved for ages 16+</td>
<td>60%</td>
<td>93%</td>
<td>Booster: 1 dose 12 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ages 16 and above</td>
<td>52%</td>
<td>95%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderna Spikevax (mRNA-1273)</td>
<td>Phase 3 (30,000)</td>
<td>100%</td>
<td>93%</td>
<td>Adult: 1 dose 5 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELA approved for ages 16+</td>
<td>80%</td>
<td>93%</td>
<td>Booster: 1 dose 12 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ages 18 and above</td>
<td>86.7%</td>
<td>86%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen/Ad (Ad26.COV2.S)</td>
<td>Phase 3 (43,223)</td>
<td>67%</td>
<td>94%</td>
<td>Adult: 1 dose 2 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELA limited to certain</td>
<td>60%</td>
<td>93%</td>
<td>Booster: 1 dose 12 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>populations (EUA approved</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>for ages 16+ and older)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxford/ AstraZeneca (ChAdOx1)</td>
<td>Phase 3 (30,000)</td>
<td>76%</td>
<td>82%</td>
<td>Adult: 1 dose 2 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Considering bypassing EOA</td>
<td></td>
<td></td>
<td>Booster: 1 dose 12 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>approval or not applying</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>for approval in the U.S.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novavax (MVX-CoV2373)</td>
<td>Phase 3 (55,000)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Awaiting final review by</td>
<td>90.4%</td>
<td>100%</td>
<td>Adult: 1 dose 2 months from first dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ELA</td>
<td></td>
<td></td>
<td>Booster: 1 dose 12 months from first dose</td>
</tr>
</tbody>
</table>

### COVID-19 VACCINE INFORMATION

- **PEDIATRICS**
- **ADDITIONAL DOSE/BOOSTER FOR MRNA VACCINES**

#### TYPE
- **MESSENGER RNA**
- **VIRAL VECTOR**
- **PROTEIN SUBUNIT**

#### Efficacy
- **Efficacy of Pfizer-BioNTech (Comirnaty)**
  - Ages 16 and above: 93% effective against hospitalization
  - Ages 12 and above: 93% effective against hospitalization
- **Efficacy of Moderna Spikevax**
  - Ages 16 and above: 86.7% effective against infection
  - Ages 16 and above: 86.7% effective against hospitalization
- **Efficacy of Janssen/Ad**
  - Ages 16 and above: 67% effective against infection
  - Ages 16 and above: 77% no reduction in effectiveness including against Delta variant
- **Efficacy of Oxford/AstraZeneca (ChAdOx1)**
  - Ages 16 and above: 76% effective against hospitalization
  - Ages 16 and above: 100% effective against hospitalization
- **Efficacy of Novavax**
  - Ages 12 and above: 90.4% effective against hospitalization

#### Timing
- **Pfizer-BioNTech (Comirnaty)**
  - Ages 16 and above: 52% effective against hospitalization, 95% effective against severe disease
- **Modernat Spikevax**
  - Ages 16 and above: 80% effective against hospitalization
- **Janssen/Ad**
  - Ages 16 and above: 67% effective against hospitalization
- **Oxford/AstraZeneca (ChAdOx1)**
  - Ages 16 and above: 76% effective against hospitalization
- **Novavax**
  - Ages 12 and above: 90.4% effective against hospitalization

#### Additional Doses/Boosters
- **Pfizer-BioNTech (Comirnaty)**
  - Ages 16 and above: 5 months from first dose
- **Modernat Spikevax**
  - Ages 16 and above: 5 months from first dose
- **Janssen/Ad**
  - Ages 16 and above: 2 months from first dose
- **Oxford/AstraZeneca (ChAdOx1)**
  - Ages 16 and above: 2 months from first dose
- **Novavax**
  - Ages 12 and above: 2 months from first dose

#### Additional Information
- **Disclaimer**
  - The information contained in this vaccine information sheet is intended to assist in the planning, administration, and education of health-care providers and is subject to the professional judgment and interpretation of the user. ASHP will continue to advocate on behalf of our members and support COVID-19 vaccine planning efforts; a number of resources are available at ashp.org/covid-vaccine.